Richard Hullihen, CEO of Polarean Imaging PLC (LON:POLX), brings Proactive London's Andrew Scott up to date on developments since their IPO back in March.
The company's recently raised US$4mln to complete their clinical trials and submit an NDA for the FDA.
''We're very happy to now have that clearly in our sights and a straight run through to completion on the trials'', Hullihen says.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE